Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases

US6133260A · kind A · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Michael Matzke · Wuppertal, DE
• Uwe Petersen · Leverkusen, DE
• Thomas Jaetsch · Cologne, DE
• Stephan Bartel · Bensberg, DE
• Thomas Schenke · Odenthal, DE
• Thomas Himmler · Odenthal, DE
• Bernd Baasner · Bensberg, DE
• Hans-Otto Werling · Wuppertal, DE
• Klaus Schaller · Wuppertal, DE
• Harald Labischinski · Wuppertal, DE

Key dates

• Filing date: Jun 14, 1999
• Grant date: Oct 17, 2000
• Expiry date: Jun 14, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.